Figure 2. A) Effect of JV-GL1 and butaprost on IOP of
SI-OHT mice relative to the pre-treatment time point (δIOP). Single,
bilateral topical applications of 0.01% JV-GL1 to SI-OHT C57BL/6J mice
(first red arrow) reduced IOP by -2.3 [-3.4, -1.2] mmHg
(P =0.01; n=9) after 3 hours and maintained significant
suppression for up to 6 days (-2.8 [-3.7, -2.0]; P =0.001;
n=9). Comparatively, 0.01% butaprost reduced IOP after 3 hours by -2.5
[-4.2, -1.0] mmHg, returning to pre-treatment levels by the
following 2-day time point (-0.8 [-1.5, 0.0] mmHg; P =0.6;
n=9). A second unilateral topical application of 0.01% JV-GL1 (second
red arrow) significantly reduced IOP of the treated eye by -2.3 [-3.4,
-1.2] mmHg after 3 days, compared to contralateral vehicle treated eye
(P =0.04, n=9). Error bars are 95% confidence intervals.B) 3 days after treatment with JV-GL1, outflow facility was not
significantly altered (18% [-7%, 50%]; P=0.2, n=9 pairs) relative
to vehicle treated eyes of SI-OHT C57BL/6J mice. Each data point shows
the relative difference in reference facility,\(\text{\ C}_{r}\),
between paired eyes comparing the treated with respect to the untreated
control eye. The error bars represent the 95% confidence intervals on
the relative difference in \(\text{\ C}_{r}\). The light shaded region
represents the best estimate of the sample distribution, with the
geometric mean and two-sigma limits represented by the thick and thin
horizontal white lines respectively. Dark central bands within the
distribution represent the 95% CI on the estimated mean.